Pfiz­er's Ix­i­fi gets ap­proved as third Rem­i­cade biosim­i­lar; No­vo Nordisk li­cens­es re­MYN­D's di­a­betes pro­gram in po­ten­tial €350M deal

→ A third knock­off is com­ing af­ter J&J’s Rem­i­cade as the FDA ap­proved Pfiz­er’s $PFE mon­o­clon­al an­ti­body Ix­i­fi for a list of in­di­ca­tions in­clud­ing rheuma­toid arthri­tis, Crohn’s dis­ease, ul­cer­a­tive col­i­tis and plaque pso­ri­a­sis. Pfiz­er sub­mit­ted a BLA in April, fol­low­ing the launch of its first Rem­i­cade biosim­i­lar — In­flec­tra, picked up when the phar­ma gi­ant ac­quired Hos­pi­ra — in Oc­to­ber of 2016. Al­so in April: Sam­sung Bioepis got the green light for its own copy­cat Ren­flex­is, which it went on to sell at 65% of J&J’s list price. Giv­en that Pfiz­er on­ly of­fered a 15% dis­count on In­flec­tra,the pric­ing of this new drug will like­ly be close­ly watched.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER